I am a surgical oncologist with a practice dedicated exclusively to the treatment of breast cancer. For almost 20 years, I have used my skills to provide the highest quality surgical care to women with breast cancer. I spend two full days in the operating room each week, and I see outpatients in the new Evelyn H. Lauder Breast Center.
My many years of education and training — including graduating summa cum laude from Pomona College, receiving my MD from Harvard Medical School, and completing my surgical training at Cornell University and Memorial Sloan Kettering — prepared me for the challenges of caring for women with breast cancer. I received the American Cancer Society’s Clinical Oncology Career Development award early in my career for my research. I have been honored for many years by being listed in “Top Doctors, NY Metro Area,” “America’s Top Doctors for Cancer,” “New York Super Doctors,” and in New York Magazine’s “Best Doctors in New York.”
My research interests include exploring diagnostic and treatment options for patients with ductal carcinoma in situ (DCIS), in which cancer cells are confined within the ducts of the breast and have not invaded into the surrounding breast tissue outside of the ducts. The diagnosis of DCIS has increased exponentially over the past two decades. Yet, the recurrence rates for women with DCIS treated with breast-conserving surgery has not been as low as that of women with the more common invasive breast cancer.
In women with DCIS I found that women of younger ages are at higher risk for local recurrence. I also found that the volume of tissue removed from the breast and the number and distance of ducts containing DCIS from the margin of the resected tissue are related to chance of recurrence. I have examined the various factors that influence the risk of local recurrence after breast conserving surgery for DCIS, and created a risk prediction model, called a nomogram, to help clinicians and patients estimate the risk of recurrence. This tool has been validated in at least two different populations to date, and will hopefully help clinicians and women weigh the various treatment options for DCIS.
Another area of special interest is sentinel lymph node biopsy. This is a method in which the breast tissue is “mapped” to identify one or a few nodes to which a woman’s breast cancer would first metastasize (spread). I developed a predictive tool called a breast cancer nomogram that calculates the likelihood of additional lymph node metastases in breast-cancer patients who have metastasis in a sentinel node. This helps patients and doctors make decisions about the pros and cons of axillary dissection (standard removal of most or all of the underarm lymph nodes).
This nomogram has been widely adopted and validated at dozens of institutions around the world. We also developed a second nomogram to help a woman with breast cancer predict the risk of having sentinel node metastases. This nomogram can help a woman understand her risk after she’s had a breast biopsy but before the results of the sentinel node biopsy are available.
My colleagues and I also investigated patients’ quality of life after breast surgery. In a prospective study that we conducted over several years, we compared the frequency of sensory changes and lymphedema (arm swelling) after sentinel node biopsy (removing a selected one or a few lymph nodes) to that of axillary dissection (conventional surgery to remove most or all of the lymph nodes under the arm).
In order to share information that we have learned about breast cancer at Memorial Sloan Kettering, I have lectured extensively, both nationally and internationally, and authored many manuscripts on topics in breast cancer. You can view a listing of my publications in PubMed by clicking on the PubMed icon below.
- Clinical Expertise: Breast Cancer
- Languages Spoken: English
- Education: MD, Harvard Medical School
- Residencies: The New York Hospital/Cornell Medical Center
- Fellowships: Cornell University Medical College
- Board Certifications: Surgery
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Kimberly J. Van Zee
Clinical Trials Co-Investigated by Kimberly J. Van Zee
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more